New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
10:26 EDTANF, ATK, AVY, VTR, QLIK, LRY, INCY, BBRY, LM, CNQ, TGT, MSFT, JNS, CQP, APAM, AYI, BIDU, WLH, STI, M, IRWD, BMYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Abercrombie & Fitch (ANF) upgraded to Buy from Neutral at Janney Capital... Artisan Partners (APAM) upgraded to Buy from Neutral at Goldman... BlackBerry (BBRY) upgraded to Sector Perform from Underperform at RBC Capital... Bristol-Myers (BMY) upgraded to Overweight from Equal Weight at Barclays... Cheniere Energy Partners LP (CQP) upgraded to Buy from Neutral at Citigroup... Incyte (INCY) upgraded to Overweight from Equal Weight at Barclays... Ironwood (IRWD) upgraded to Outperform from Market Perform at BMO Capital... Janus Capital (JNS) upgraded to Neutral from Sell at Goldman... Liberty Property (LRY) upgraded to Buy from Neutral at UBS... Macy's (M) upgraded to Buy from Neutral at Goldman... Microsoft (MSFT) upgraded to Overweight from Equal Weight at Barclays... Qlik Technologies (QLIK) upgraded to Buy from Hold at Jefferies... SunTrust (STI) upgraded to Conviction Buy from Buy at Goldman... Target (TGT) upgraded to Buy from Neutral at Goldman... Ventas (VTR) upgraded to Buy from Neutral at UBS... William Lyon Homes (WLH) upgraded to Overweight from Neutral at JPMorgan... Canadian Natural (CNQ) upgraded to Outperform from Market Perform at BMO Capital... Avery Dennison (AVY) upgraded at Topeka... Baidu (BIDU) upgraded to Buy from Hold at Maxim... ATK (ATK) upgraded to Buy from Hold at Argus... Legg Mason (LM) upgraded to Neutral from Negative at Susquehanna... Acuity Brands (AYI) upgraded to Neutral from Underperform at Wedbush.
News For ANF;APAM;BBRY;BMY;CQP;INCY;IRWD;JNS;LRY;M;MSFT;QLIK;STI;TGT;VTR;WLH;CNQ;AVY;BIDU;LM;ATK;AYI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
December 9, 2014
08:25 EDTBMYBristol-Myers data positive, says BMO Capital
Subscribe for More Information
08:14 EDTMMacy's downgraded at Atlantic Equities
Subscribe for More Information
08:06 EDTMMacy's downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
08:02 EDTIRWDIronwood initiates Phase IIa study of IW-9179 in diabetic gastroparesis
Subscribe for More Information
07:11 EDTINCYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
06:27 EDTMSFTSamsung, white-box makers to benefit from Microsoft Mobile exit, DigiTimes says
Subscribe for More Information
December 8, 2014
13:32 EDTBMYPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
13:21 EDTMSFTMicrosoft files appeal in case on customer data in Ireland
Microsoft said on its blog that it has filed an appeal in its ongoing case challenging a U.S. government search warrant for customer data stored in Ireland. Microsoft said it filed the appeal after a U.S. district court judge rejected the company’s argument that the warrant is illegal because it calls for the seizure of emails stored outside the United States. Reference Link
13:07 EDTINCYNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
12:40 EDTMSFTOn The Fly: Midday Wrap
Subscribe for More Information
12:13 EDTJNSJanus fund had $1.2B of assets under management at end of November, WSJ reports
According to data released by Morningstar, the Janus Global Unconstrained Bond fund, Bill Gross's new mutual fund at Janus Capital, had $1.2B of assets under management at the end of November, The Wall Street Journal reports. The data shows that the pace of monthly inflows was the highest since Gross took over the fund. Reference Link
11:48 EDTSTISunTrust downgraded to Hold from Buy at Standpoint Research
10:44 EDTMSFTDigital River grants Microsoft extestion to decide on renewing pact
Subscribe for More Information
10:20 EDTANFOptions with decreasing implied volatility
Subscribe for More Information
10:04 EDTMSFTAccenture and Microsoft launch hybrid cloud platform
Subscribe for More Information
10:00 EDTCNQOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:13 EDTCNQCanadian Natural downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Canadian Natural Resources to Neutral saying the company is likely to cut its capital spending amid lower oil prices. Citi lowered its price target for shares to $36 from $50.
05:53 EDTBMYStocks with implied volatility movement; BSX BMY
Subscribe for More Information
December 7, 2014
14:10 EDTBMYAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:06 EDTBMYBMY announces positive results in Phase 1b trial evaluating Opdivo
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use